NexMed Announces Expansion of Senior Business Development Team
26 May 2010 - 7:00AM
Business Wire
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of
products based on the NexACT® technology, today announced the
expansion of its senior business development team within NexMed
(U.S.A.), with the appointments of Linda Smibert as Vice President
of Business Development and Mark S. Wilson as Vice-President of
Technology Development. Both executives will report to Vivian Liu,
the Company’s Executive Vice-President.
In her new position, effective May 26, 2010, Ms. Smibert will
spearhead the out-licensing of NexMed’s pre-clinical and clinical
product pipeline. Prior to joining the Company, Ms. Smibert served
for eight years as Senior Director and Director of Business
Development at Santarus, Inc., where she led licensing deals with
GlaxoSmithKline and Norgine, a co-promotion arrangement with Otsuka
America, and contributed to alliances with Schering-Plough and
others. Ms. Smibert has over 20 years of experience in the
pharmaceutical industry, and, in addition to her tenure at
Santarus, has held a variety of business development and strategic
planning management functions at Bristol-Myers Squibb in the U.S.
and in Canada, as well as with Zeneca in Canada and the U.K. Ms.
Smibert earned her B.A. from the University of British Columbia and
an MBA from the University of Toronto.
In his new position, effective May 24, 2010, Mr. Wilson is
responsible for the out-licensing of the NexACT technology. Mr.
Wilson brings to NexMed over 20 years of experience in the
biopharmaceutical, diagnostic and medical device industries. Prior
to joining NexMed, he was Entrepreneur-in-Residence at CONNECT in
San Diego, where he provided business start-up strategy,
development and sourcing consulting services to local companies.
Prior to that, he served for five years as Vice President of
Business Development at Halozyme Therapeutics, where, among others,
he was responsible for initiating the company’s $612 million
alliance with F. Hoffmann-La Roche and for various alliances with
Baxter Healthcare. Mr. Wilson earned a B.S. in Mechanical
Engineering from the University of California, Berkeley, and an MBA
from the University of California, Los Angeles.
Commenting on today’s news, Bassam Damaj, Ph.D., President and
Chief Executive Officer of NexMed, stated, “We are very pleased to
welcome both Linda and Mark to NexMed at this critical stage in our
corporate development. Our stated goal is to actively pursue key
partnership opportunities for both our NexACT technology and
pipeline products. Given the increasing number of licensing
inquiries that we have received, these two highly regarded business
development executives will play a key role in our growth going
forward, leveraging their expertise and strong industry
relationships to broaden the Company’s visibility and partnership
opportunities in 2010 and beyond.”
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company’s goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT® drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed is actively pursuing
partnering opportunities for its NexACT-based treatments for
onychomycosis, psoriasis, sexual dysfunction and cancer. For
further information on NexMed and its subsidiaries, visit the
following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Forward-Looking Statement Safe
Harbor
Statements under the Private Securities Litigation Reform Act:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company. For
example, and without limitation, there can be no assurance that the
Company will be able to successfully license its NexACT technology
or proprietary products under development.
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From May 2024 to Jun 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Jun 2023 to Jun 2024